Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEN15596 in irritable bowel syndrome
2008-000214-71Phase 2Completed
- Sponsor
- Menarini Group
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ibodutant in irritable bowel syndrome (IBS) (4 arms), sponsored by Menarini Group. Primary endpoint: Response for relief of overall IBS symptoms (SGA). Started Apr 2008; status: completed.
02
Drugs
ibodutant
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2008-000214-71.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000214-71.